Table 2.

Response to anti-EGFR therapy in patients with stage IV KRAS/BRAF wild-type, PI3K/Akt pathway–mutant colorectal carcinomas

PI3K pathway mutationSynchronous interventions/chemotherapiesOutcome
PIK3CA R88QFluorouracil, irinotecan, floxuridine, hepatic resectionNo evidence of disease for at least 24 months
PIK3CA E542KIrinotecanRadiologic response for at least 5 months, including disappearance of multiple 1- to 2-cm hepatic metastases with stable size of peritoneal metastases
PIK3CA E542VNoneStable disease for 6 months
PIK3CA E542KIrinotecanStable disease at 1 month, progression of disease at 3 months
PIK3CA E545KIrinotecan, fluorouracil, leucovorin, radiofrequency ablation, hepatic resection and infusion pumpStable disease for at least 9 months
PIK3CA E545KIrinotecanStable disease for 10 months before progression
PIK3CA E545KIrinotecanNo evidence of disease for at least 14 months (macroscopic disease resected before cetuximab)
PIK3CA H1047RYttrium-90Stable disease for 6 months
AKT1 E17KIrinotecanProgression of disease without any period of stabilization or response
AKT1 E17KIrinotecanProgression of disease without any period of stabilization or response